Dipeptidyl Peptidase (DPP)-4 Inhibitor Impairs the Outcomes of Patients with Type 2 Diabetes Mellitus After Curative Resection for Colorectal Cancer
Open Access
- 22 November 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 1 (2) , 106-114
Abstract
Dipeptidyl peptidase IV inhibitor (DPP-4i) has been shown to act either as a promoter or as a suppressor for cancer. Although epidemiologic studies suggest that DPP-4i does not correlate with the development of malignancies, its effects on cancer metastases are controversial. We evaluated the impact of DPP-4i on postoperative outcomes of the diabetic patients with colorectal cancer and microscopic features of the resected tumors. In 260 consecutive patients with type 2 diabetes mellitus (T2DM) who underwent curative resection of colorectal cancer, the correlation between DPP-4i use and prognosis was retrospectively examined. Expression of Zeb1 on tumor cells and density of infiltrating immune cells were quantitatively evaluated with multicolor IHC in 40 tumors from DPP-4i users, 40 tumors from propensity score–matched users, and 40 tumors from nonusers. Postoperative disease-free survival (DFS) was significantly lower in 135 patients treated with DPP-4i compared with 125 nontreated patients [5-year DFS, 73.7% vs. 87.4%; HR, 1.98; 95% confidence interval (CI), 1.05–3.71; P = 0.035]. IHC revealed that the number of Zeb1+ tumor cells increased in tumors from DPP-4i–treated patients than tumors from nonusers (P < 0.01). The densities of CD3+ and CD8+ T cells were significantly lower in tumors from DPP-4i users (P < 0.01) with decreased density of tertiary lymphoid structures (P < 0.001). However, the density of M2-type tumor-associated macrophages with CD68+ CD163+ phenotypes was significantly higher (P < 0.01) in tumors from DPP-4i users. Exposure of colorectal cancer to DPP-4i may accelerate epithelial-to-mesenchymal transition (EMT) creating a tumor-permissive immune microenvironment, which might impair the outcomes of the patients with colorectal cancer and T2DM.Keywords
Funding Information
- MEXT | Japan Society for the Promotion of Science (19K09225)
This publication has 56 references indexed in Scilit:
- Diabetes, antihyperglycemic medications and cancer riskCurrent Opinion in Endocrinology, Diabetes and Obesity, 2013
- Impact of diabetes on overall and cancer-specific mortality in colorectal cancer patientsJournal of Cancer Research and Clinical Oncology, 2013
- The Links Between Insulin Resistance, Diabetes, and CancerCurrent Diabetes Reports, 2012
- Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activationBiochemical and Biophysical Research Communications, 2012
- A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid CancerExperimental Diabetes Research, 2012
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based TherapiesGastroenterology, 2011
- Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytesCellular and Molecular Life Sciences, 2010
- The dipeptidyl peptidase IV family in cancer and cell biologyThe FEBS Journal, 2010
- Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell functionTrends in Immunology, 2008
- DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cellsRegulatory Peptides, 2006